PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › STAR0602

Drugs in development · updated 30 October 2026

STAR0602: clinical trials and development status

Development codeNot approved in the USNo EMA authorisation

As of 30 October 2026 STAR0602 is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 28 diseases. The most advanced phase is I–II.

3Active trials
I–IIMost advanced phase
28Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow STAR0602 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Lung neoplasmI–II2NCT07902921
Non-small-cell lung carcinomaI–II2NCT07902921
Abdominal neoplasmI–II1NCT05592626
Basal-cell carcinoma of the skinI–II1NCT05592626
Biliary tract neoplasmI–II1NCT05592626
Bladder neoplasmI–II1NCT05592626
CarcinomaI–II1NCT05592626
Colorectal neoplasmI–II1NCT05592626
Endometrial neoplasmI–II1NCT05592626
Epstein–Barr virus infectionI–II1NCT05592626
Esophageal neoplasmI–II1NCT05592626
Gastrointestinal neoplasmI–II1NCT05592626
Genital Neoplasms, FemaleI–II1NCT05592626
Head and neck neoplasmsI–II1NCT05592626
Lung small cell carcinomaI–II1NCT05592626
MelanomaI–II1NCT05592626
Merkel cell carcinomaI–II1NCT05592626
Microsatellite instabilityI–II1NCT05592626
Nasopharyngeal neoplasmI–II1NCT05592626
NeoplasmI–II1NCT05592626
Papillomavirus infectionsI–II1NCT05592626
Prostatic NeoplasmsI–II1NCT07902921
Stomach neoplasmI–II1NCT05592626
ThymomaI–II1NCT07902921
Urogenital neoplasmI–II1NCT05592626
Uterine cervix neoplasmI–II1NCT05592626
Vulvar diseaseI–II1NCT05592626
Vulvar neoplasmI–II1NCT05592626

Everything on STAR0602

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch